BREVIBLOC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Brevibloc, and when can generic versions of Brevibloc launch?
Brevibloc is a drug marketed by Baxter Hlthcare and is included in one NDA.
The generic ingredient in BREVIBLOC is esmolol hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Brevibloc
A generic version of BREVIBLOC was approved as esmolol hydrochloride by HIKMA on August 10th, 2004.
Summary for BREVIBLOC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Clinical Trials: | 16 |
Patent Applications: | 703 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for BREVIBLOC |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BREVIBLOC |
What excipients (inactive ingredients) are in BREVIBLOC? | BREVIBLOC excipients list |
DailyMed Link: | BREVIBLOC at DailyMed |
Recent Clinical Trials for BREVIBLOC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Zagazig University | Phase 2 |
Cristália Produtos Químicos Farmacêuticos Ltda. | Phase 4 |
University Hospital Bispebjerg and Frederiksberg | Phase 4 |
Pharmacology for BREVIBLOC
Drug Class | beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic beta-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for BREVIBLOC
US Patents and Regulatory Information for BREVIBLOC
Expired US Patents for BREVIBLOC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-003 | Aug 15, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-006 | Feb 25, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-007 | May 28, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-007 | May 28, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-003 | Aug 15, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-006 | Feb 25, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BREVIBLOC
See the table below for patents covering BREVIBLOC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 880001539 | ⤷ Try a Trial | |
Japan | 2013151572 | ESMOLOL FORMULATION | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 8201869 | ⤷ Try a Trial | |
South Korea | 20020093839 | ⤷ Try a Trial | |
South Korea | 100889090 | ⤷ Try a Trial | |
Brazil | 0203517 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |